ChromaDex (NASDAQ:CDXC – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $11.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 40.31% from the stock’s previous close.
CDXC has been the subject of a number of other reports. StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 6th. LADENBURG THALM/SH SH upped their target price on shares of ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a report on Wednesday, March 5th.
View Our Latest Analysis on CDXC
ChromaDex Price Performance
Institutional Investors Weigh In On ChromaDex
Several hedge funds have recently modified their holdings of the stock. USA Financial Formulas acquired a new stake in ChromaDex in the fourth quarter valued at approximately $25,000. State of Wyoming acquired a new stake in ChromaDex during the 4th quarter valued at $39,000. Mercer Global Advisors Inc. ADV acquired a new stake in ChromaDex during the 4th quarter valued at $53,000. Truist Financial Corp purchased a new stake in ChromaDex during the 4th quarter worth $54,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in ChromaDex in the 4th quarter worth $67,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.
ChromaDex Company Profile
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Recommended Stories
- Five stocks we like better than ChromaDex
- What Are Trending Stocks? Trending Stocks Explained
- Meta Platforms: Can LLaMA Drive Long-Term Stock Growth?
- What is a Death Cross in Stocks?
- 3 Unique and Dominant Consumer Staples ETF Plays
- How to trade penny stocks: A step-by-step guide
- 3 Dividend Stocks Offering Higher Yields and Bullish Forecasts
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.